Huasen Pharmaceuticals (002907.SZ): Product Included in the National Essential Medicines List

Gelonghui, July 9 — Huasen Pharmaceuticals (002907.SZ) announced that the National Health Commission recently released the "National Essential Medicines List" (2026 Edition), which will take effect on September 1, 2026. Upon verification, five products from Chongqing Huasen Pharmaceutical Co., Ltd. have been newly included in this edition of the list.

Gelonghui FinanceJul 9 18:50

Express News | Innovative drug stocks surged again in the afternoon, with Huasen Pharmaceutical hitting its daily trading limit.

BreakingsJul 9 13:04

Huasen Pharmaceuticals (002907.SZ): Tongxie Ning Granules approved as the first nationally recognized Class II protected traditional Chinese medicine product

Huasen Pharmaceutical Co., Ltd. (SZSE: 002907) announced that the National Medical Products Administration (NMPA) recently published Announcement No. 37 on Protected Traditional Chinese Medicine Varieties (NMPA Announcement [2026] No. 57), granting the company's Tongxie Ning Granules the status of the first protected Class II traditional Chinese medicine variety. The protection certificate number is ZYB2072026018, with a seven-year protection period effective from the date of the announcement.

Zhitong FinanceJun 25 16:13

Express News | Innovative drug stocks rebounded amid intraday volatility, with NuoSiLanDe surging nearly 20%.

BreakingsJun 18 10:28

Huasen Pharmaceuticals (002907.SZ): Shareholder Liu Xiaoying reduced her holdings by 4.176 million shares of the company.

Gelonghui, June 15 — Huasen Pharmaceuticals (002907.SZ) announced that the company received a "Notice of Completion of Share Reduction" from Ms. Liu Xiaoying on June 12, 2026. As of the date of this announcement, the time period for the share reduction plan has expired. From April 30, 2026, to June 12, 2026, Ms. Liu Xiaoying reduced her holdings by 4,176,000 shares, representing 1% of the company's total share capital, through block trades, and the transferee is prohibited from selling the acquired shares within six months following the transfer. Following this change in equity interest, Ms. Liu Xiaoying holds 25,062,816 shares of the company, representing

Gelonghui FinanceJun 15 17:51

Huasen Pharmaceuticals (002907.SZ) 2025 annual profit distribution: RMB 0.40 per 10 shares

Gelonghui, May 26 — Huasen Pharmaceuticals (002907.SZ) announced its 2025 annual profit distribution implementation notice. The Company’s 2025 annual profit distribution plan is as follows: based on the current total share capital of 417,596,314 shares, a cash dividend of RMB 0.4 per 10 shares (tax inclusive) will be distributed to all shareholders. The record date for this profit distribution is June 3, 2026, and the ex-dividend date is June 4, 2026.

Gelonghui FinanceMay 26 17:10